Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-15
2008-08-19
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S106000, C544S111000, C544S144000, C544S358000, C546S184000, C546S192000, C548S469000, C548S484000, C548S486000, C514S231200, C514S418000
Reexamination Certificate
active
07414054
ABSTRACT:
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
REFERENCES:
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6316635 (2001-11-01), Tang et al.
patent: 6350747 (2002-02-01), Glennon et al.
patent: 6762180 (2004-07-01), Roth et al.
patent: 6765012 (2004-07-01), Andrews et al.
patent: 6818632 (2004-11-01), Glennon et al.
patent: 6855710 (2005-02-01), Walter et al.
patent: 7015220 (2006-03-01), Andrews et al.
patent: 7098236 (2006-08-01), Andrews et al.
patent: 19824922 (1999-12-01), None
patent: WO 91/15495 (1991-10-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/21660 (1992-12-01), None
patent: WO 94/03427 (1994-02-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO 00/12084 (2000-03-01), None
patent: WO 01/16130 (2001-03-01), None
Glennon et al (2000): STN International HCAPLUS database, Columbus (Ohio), Accession No. 2000: 688216.
Heckel et al (2001): STN International HCAPLUS database, Columbus (Ohio), Accession No. 2001: 283925.
Plowman et al, “Receptor Tyrosine Kinases as Targets for Drug Intervention”,1994, DN&P 7(6): 334-339.
Bolen, “Nonreceptor tyrosine protein kinases”, 1993, Oncogen 8: 2025-2031.
Kendall et al, “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor”, 1994, Proc. Natl'l Acad. Sci 90: 10705-10709.
Kim et al, “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo”, Nature 362, 841-844.
Jellinek et al, “Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor”, Biochemistry 33: 10450-10456.
Takano et al, “Inhibition of Angiogenesis by a Novel Diaminoanthraquinone that Inhibits Protein Kinase C.”, 1993, Mol. Bio. Cell 4: 2072, p. 358A.
Kinsella et al, “Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel”, 1992, Experimental Cell Research, 199: 56-62.
Wright et al, “Inibition of Angiogenesis In Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032”, 1992, Journal of Cellular Phys. 152: 448-457.
Mariani et al, “Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor”,1994, Proc. Am. Assoc. Cancer Res. 35:2268; p. 381.
Castro et al, “Quantitative Image Analysis of Laser-induced Choroidal Neovascularization in Rat”, Exp. Eye Res. 2000; 71:523-55.
Wolfbeis, “Eine Effiziente Synthese Von Amino . . . ”, vol. 112, Mar. 1, 1981, pp. 369-383.
Coda et al, “Copper (II) in Organic Synthesis . . . ” vol. 117, No. 5, 1987, pp. 301-305.
Seshadri et al, “Studies on the Application of the Vilsmeier-Haack Reaction to Lactams . . . ”, Indian Journal of Chemistry, vol. 7, Jul. 1969, pp. 667-671.
Walter et al (2000): STN International CAPLUS database, Columbus (Ohio), Accession No. 2000: 227630.
Glennon et al (2000): STN International CAPLUS database, Columbus (Ohio), Accession No. 2000: 688216.
Andrews Steven W.
Malone Thomas
Wang Edward H.
Wurster Julie A.
Allergan Inc.
German Joel B.
Shameem Golam M
Stathakis Dean G.
Voet Martin A.
LandOfFree
3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002662